To evaluate the safety and anti-HBV efficacy of γδT cells.
In this clinical trial, we will thoroughly evaluate the safety of in vitro expanded γδT cells, including allogeneic originated γδT cells, in clinical treatment of active HBV. At the same time, we will carefully and thoroughly examine and evaluate the clinical efficacy of γδT cells against active HBV, including lowering speed of DNA copy number, and the transferring rate of HBeAg from positive to negative.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Patients are treated via intravenous infusion of in vitro-activated allogeneic γδ Tcells every two weeks, 12 times in total (6 months).
Guagnzhou Qiaokang Hospital
Guangzhou, Guangdong, China
DNA copy number
Whether or not the DNA copy number in patients can be lowered more faster than those do not received T cell treatment in 6 months.
Time frame: 6 months
Negative conversion rate of HbeAg
We will evaluate whether or not γδT Cells treatment could speed up Negative conversion rate of HbeAg.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.